With a single discovery, CureVac opened the world up to the potential of mRNA to treat diseases and create vaccines. Officially founded in 2000, CureVac is the world’s first company to successfully harness mRNA for medical purposes—because we …

CureVac reports positive interim Phase 1 data for its COVID-19 vaccine candidate, CVnCoV: Data show balanced immune response with strong induction of binding and neutralizing antibodies and first indications of T cell activation

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

Through our proprietary mRNA technology we are able to directly give the body the information it needs to fight disease. Driven by passion for patients, we seek life-altering results for humanity. We harness the elegant principles of biology to optimize mRNA therapeutic solutions. CureVac is developing a new class of medicines — for life.

CureVac ist ein globales biopharmazeutisches Unternehmen mit über 20 Jahren Erfahrung in der Entwicklung der mRNA-Technologie für medizinische Zwecke.

2022年8月18日 · CV0501 is CureVac’s first COVID-19 vaccine candidate applying chemically modified mRNA from the COVID-19 vaccine program developed in collaboration with GSK. It is based on CureVac’s advanced second-generation mRNA backbone.

2023年8月1日 · CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in the Phase 2 study of monovalent and bivalent modified mRNA COVID-19 vaccine candidates, developed in ...

2024年1月5日 · CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive interim data from the ongoing Phase 2 study assessing monovalent and bivalent modified vaccine candidates against COVID-19.

Our path towards a new class of safe and effective therapeutics started 20 years ago, with the unexpected discovery by CureVac founder Ingmar Hoerr of the therapeutic potential of messenger RNA (mRNA).

“I am very excited to be part of CureVac and to help develop new therapeutic options against severe diseases. mRNA technology has the potential to revolutionize medicine and to be accessible to all. It is CureVac's spirit.”